Display options
Cite
Moudi E, Kasaeeyan AA. Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation. Nephrourol Mon. 2016;8(1):e32286doi: 10.5812/numonthly.32286.
Moudi, E., & Kasaeeyan, A. A. (2016). Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation. Nephro-urology monthly, 8(1), e32286. https://doi.org/10.5812/numonthly.32286
Moudi, Emadouddin, and Kasaeeyan, Ali Akbar. "Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation." Nephro-urology monthly vol. 8,1 (2016): e32286. doi: https://doi.org/10.5812/numonthly.32286
Moudi E, Kasaeeyan AA. Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation. Nephrourol Mon. 2016 Jan 27;8(1):e32286. doi: 10.5812/numonthly.32286. eCollection 2016 Jan. PMID: 26981497; PMCID: PMC4780280.
Copy Download .nbib Format: NLM
Share it on

Nephrourol Mon. 2016 Jan 27;8(1):e32286. doi: 10.5812/numonthly.32286. eCollection 2016 Jan.

Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation.

Nephro-urology monthly

Emadouddin Moudi, Ali Akbar Kasaeeyan

Affiliations

  1. Department of Urology, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, IR Iran.
  2. Department of Urology, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, IR Iran; Clinical Research Development Center, Shahid Beheshti Hospital, Babol University of Medical Sciences, Babol, IR Iran.

PMID: 26981497 PMCID: PMC4780280 DOI: 10.5812/numonthly.32286

Abstract

BACKGROUND: Several recent studies have investigated the therapeutic role of phosphodiesterase type 5 (PDE5) inhibitors in premature ejaculation (PE) used in the treatment of erectile dysfunction.

OBJECTIVES: In the present research, the efficacy of paroxetine alone and paroxetine plus tadalafil was compared in patients referred because of premature ejaculation.

PATIENTS AND METHODS: This quasi-experimental study was performed on 100 consecutive 17 to 49-year-old potent men with premature ejaculation and without any clear organic disease. All patients had lifelong PE with an intravaginal ejaculation latency time (IELT) shorter than 1.5 minutes. Informed consent was obtained from all patients who were randomly divided into two groups using a computer-generated random tabulation list. In group A, patients received 10 mg paroxetine daily, in addition to four hours before planned sexual activity. In group B, 10 mg paroxetine was taken daily, plus 10 mg tadalafil one hour before planned sexual activity. The duration of the intervention was six months and patients were evaluated for IELT three and six months after the beginning of therapy.

RESULTS: The mean age of patients in groups A and B were 33 ± 9.6 and 31.2 ± 9.3 years, respectively (P = 0.368). The mean number of intercourses were 1.08 ± 0.6 and 1.12 ± 0.6 per week in groups A and B, respectively (P = 0.791). Mean IELT at the 3-month follow up in groups A and B was 4.5 ± 1.5 and 5 ± 2.4 minutes, respectively (P = 0.285) and at the 6-month follow up was 4.8 ± 1 and 5.3 ± 2 minutes, respectively (P = 0.278).

CONCLUSIONS: The results of the study show that tadalafil can increase the mean IELT and can be used for treatment of premature ejaculation in combination with paroxetine.

Keywords: Paroxetine Tadalafil Plus Paroxetine and Paroxetine; Premature Ejaculation; Serotonin Uptake Inhibitors

References

  1. J Sex Med. 2004 Jul;1(1):58-65 - PubMed
  2. J Urol. 2002 Dec;168(6):2486-9 - PubMed
  3. J Sex Marital Ther. 1989 Summer;15(2):130-4 - PubMed
  4. Urology. 2006 Feb;67(2):388-91 - PubMed
  5. Int J Impot Res. 2001 Feb;13(1):41-5 - PubMed
  6. Am J Psychiatry. 2007 Feb;164(2):198-200 - PubMed
  7. J Sex Med. 2005 May;2(3):368-75 - PubMed
  8. World J Urol. 2005 Jun;23(2):102-8 - PubMed
  9. J Sex Med. 2006 Sep;3 Suppl 4:318-23 - PubMed
  10. BJU Int. 2006 Aug;98(2):259-72 - PubMed
  11. Drugs. 2007;67(4):547-68 - PubMed
  12. Eur Urol. 2010 May;57(5):804-14 - PubMed
  13. Zhonghua Nan Ke Xue. 2004 May;10(5):366-7, 370 - PubMed
  14. J Sex Med. 2005 Jul;2(4):508-12 - PubMed
  15. J Sex Med. 2010 Sep;7(9):2947-69 - PubMed
  16. J Clin Psychopharmacol. 1998 Aug;18(4):274-81 - PubMed
  17. Zhonghua Nan Ke Xue. 2005 Jul;11(7):520-2, 525 - PubMed
  18. J Urol. 2007 Mar;177(3):1059-64; discussion 1064 - PubMed
  19. Int J Impot Res. 2004 Aug;16(4):369-81 - PubMed
  20. Int J Androl. 2006 Oct;29(5):503-09 - PubMed
  21. Eur Urol. 2007 Nov;52(5):1331-9 - PubMed
  22. Urology. 2003 Jan;61(1):197-200 - PubMed
  23. J Clin Psychopharmacol. 2001 Dec;21(6):556-60 - PubMed
  24. Int J Impot Res. 2006 Sep-Oct;18 Suppl 1:S5-13 - PubMed
  25. BJU Int. 2008 Sep;102(7):824-8 - PubMed

Publication Types